From Bell Potter 24/3/17:-recommendation and target price of $30.00
Enhanced Understanding To Drive Revenue Growth
In our view the current share price of $17.39 can be justified from the current base of
~12,000 dose sales annually, however, if the abstract reports that the SARAH study
did not meet the primary endpoint, further price volatility is possible.
We believe the enhanced understanding of SIR spheres arising from the SARAH study
and when its use is optimal should enhance future dose sales growth and our forecast
includes this assumption. Conversely, the downside risk for revenues is reasonably
small as SIR spheres would continue to be used as salvage therapy in HCC.
There are no changes to forecast earnings at this time and we maintain our Buy
Ann: SARAH Abstract Embargoed Until EASL/ILC Meeting, page-70
-
- There are more pages in this discussion • 13 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add SRX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
18.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $77.74M | |||
| Open | High | Low | Value | Volume |
| 18.0¢ | 18.0¢ | 18.0¢ | $10.1K | 56.10K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 36209025 | 18.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 18.5¢ | 4384259 | 22 |
View Market Depth
| Last trade - 15.18pm 13/09/2024 (20 minute delay) ? |
| SRX (ASX) Chart |